

SUPPLEMENTARY MATERIAL

Ibrutinib in Combination With Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study

M. Tempero,¹ D.-Y. Oh,² J. Tabernero,³ M. Reni,⁴ E. Van Cutsem,⁵ A. Hendifar,⁶
D.-T. Waldschmidt,⁷ N. Starling,⁸ J.-B. Bachet,⁹ H.-M. Chang,¹⁰ J. Maurel,¹¹
R. Garcia-Carbonero,¹² S. Lonardi,¹³ L.M. Coussens,¹⁴ L. Fong,¹ L.C. Tsao,¹⁵ G. Cole Jr,¹⁵ D.
James,¹⁵ T. Macarulla³

¹ University of California San Francisco, San Francisco, California, USA; ² Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; ³ Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UICC, CIBERONC Barcelona, Spain; ⁴ San Raffaele Hospital Scientific Institute, Milan, Italy; ⁵ University Hospitals Gasthuisberg/Leuven & KU Leuven, Belgium; ⁶ Cedars-Sinai Medical Center, Los Angeles, California, USA; ⁷ University of Cologne, Köln, Germany; ⁸ The Royal Marsden, London, United Kingdom; ⁹ UPMC, Sorbonne University, Pitié Salpêtrière Hospital, APHP, Paris, France; ¹⁰ University of Ulsan College of Medicine, Seoul, South Korea; ¹¹ Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; ¹² Hospital Universitario Doce de Octubre, Imas12, UCM, CNIO, CIBERONC, Madrid, Spain; ¹³ Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; ¹⁴ Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; ¹⁵ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA.

CORRESPONDING AUTHOR:

Dr. Margaret Tempero

UCSF – Mission Bay Campus / Mission Hall

550 16th Street, 6th Floor, Box 3211


San Francisco, CA 94143

USA

Tel: +1 (415) 885-3846

Email: Margaret.Tempero@ucsf.edu

Supplementary Figure S1. Forest Plots of Overall Survival by Subgroup Analysis. The sizes of the circles are proportional to the sizes of the subgroups; error bars indicate 95% confidence intervals. The dashed vertical line represents the overall treatment effect for all patients.



CRP, C-reactive protein; Ibr, ibrutinib; GCB, gemcitabine; KPS, Karnofsky Performance Score; Nab-P, nab-paclitaxel; PBO, placebo.